Tomeka Roberts, MD
Obstetrics & Gynecology · Birmingham, ALNPI 1619921509
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $29,850 of the $44,403 with a category attached, or 67.2%. Acessa Health Inc. accounts for 72.2% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2024 at $17,787 and has fallen 84.6% since, to $2,742 in 2025. Among obstetrics & gynecology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 178 payments — averaging $249.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acessa Health Inc.$32K
- Hologic Sales And Service, LLC$4K
- Pfizer$3K
- Intuitive Surgical$2K
- Myovant Sciences Inc.$915
- AbbVie$529
- plus $2K from 22 others
What the payments were for
- Consulting fees$29,85067%
- Speaking & faculty fees$3,7809%
- Travel & lodging$5,44912%
- Food & beverage$4,1939%
- Education$1,1163%
- Gifts$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acessa Health Inc.(2 entities) | 29 | $32,066 |
| Hologic Sales And Service, LLC | 26 | $3,695 |
| Pfizer | 14 | $3,159 |
| Intuitive Surgical | 14 | $2,040 |
| Myovant Sciences Inc. | 5 | $915 |
| AbbVie | 23 | $529 |
| Sumitomo Pharma America, Inc. | 7 | $226 |
| Novo Nordisk | 7 | $218 |
| Therapeuticsmd, Inc. | 10 | $216 |
| Astellas Pharma US Inc | 8 | $213 |
| Integra Lifesciences Corporation | 1 | $152 |
| Scynexis, Inc. | 7 | $133 |
| Meditrina | 1 | $125 |
| Myriad Women's Health, Inc. | 1 | $121 |
| Dexcom, Inc. | 1 | $118 |
| Aspira Women's Health Inc | 1 | $64 |
| Mayne Pharma Commercial LLC | 4 | $64 |
| Bayer | 3 | $53 |
| Lupin Inc. | 4 | $49 |
| Johnson & Johnson | 1 | $48 |
| Shield Therapeutics Inc | 2 | $45 |
| Exeltis, USA Inc. | 2 | $36 |
| AMAG Pharmaceuticals, Inc. | 2 | $31 |
| Davol Inc. | 1 | $22 |
| Axonics, Inc. | 1 | $20 |
| Minerva Surgical, Inc | 1 | $18 |
| Amgen | 1 | $16 |
| Avion Pharmaceuticals | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACESSA PROVU SYSTEM$35,049
- MYFEMBREE$1,307
- DAVINCI XI$1,000
- Da Vinci Surgical System$770
- TENOGLIDE$152
- ORIAHNN$122
- Wegovy$122
- myRisk$121
- DEXCOM G7 GSS (161)$118
- IMVEXXY$114
How this compares
$44,403 in reported general payments places this provider in the 95th percentile of 537 obstetrics & gynecology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 37 | $21,413 |
| Estradiol | 126 | $5,938 |
| Tolterodine Tartrate ErTolterodine Tartrate | 20 | $3,122 |
| ValacyclovirValacyclovir Hcl | 73 | $3,015 |
| Estradiol (Twice Weekly)Estradiol | 46 | $2,907 |
| YuvafemEstradiol | 14 | $2,401 |
| Raloxifene Hcl | 11 | $1,264 |
| DottiEstradiol | 16 | $875 |
| ProgesteroneProgesterone, Micronized | 22 | $703 |
| Fluconazole | 95 | $612 |
| Alendronate Sodium | 36 | $427 |
| Clobetasol Propionate | 18 | $414 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 20 | $262 |
| Medroxyprogesterone Acetate | 13 | $253 |
| Larin FeNorethindrone-E.Estradiol-Iron | 13 | $223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $213 | $21,41337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 537 obstetrics & gynecology providers in Alabama.
Other obstetrics & gynecology in Birmingham
- Theodore TsaltasBirmingham$853K
- Percy HudsonBirmingham$29K
- Heidi StraughnBirmingham$29K
- William HudsonBirmingham$13K
- William JohnsonBirmingham$10K
- Cynthia BrownBirmingham$10K
- Loretta PrestonBirmingham$10K
- Laura Lee JoinerBirmingham$9K
- Victoria WheelerBirmingham$8K
- Mia CowanBirmingham$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.